【Pfizer China President: Continuing to Deepen Engagement in the Chinese Market Over the Next 5 Years】Pfizer China President Jean-Christophe Pointeau (Peng Zhenke) stated in an exclusive interview that the "Pfizer China 2030 Strategy" consists of three main parts: First, accelerating the introduction of innovative drugs. Second, collaborating with the government and medical associations to improve disease diagnosis and treatment levels. Third, partnering with local biopharmaceutical companies to develop innovative products in China. The Chinese market is a strategic priority for Pfizer, and the rapid development of China's healthcare sector, continuous improvement of health insurance policies, and the acceleration of drug approval reforms have strengthened Pfizer's confidence in continuing to invest in the Chinese market. In the next five years, Pfizer will invest $1 billion in China. (Source: Jinshi Data)